Galera Therapeutics (GRTX) Competitors $0.03 +0.00 (+1.19%) As of 10:38 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock GRTX vs. OBSV, PMCB, GNPX, CVM, LIXT, RNAZ, CELZ, SLXN, AIM, and OMGAShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include ObsEva (OBSV), Nuvilex (PMCB), GENPREX (GNPX), CEL-SCI (CVM), Lixte Biotechnology (LIXT), TransCode Therapeutics (RNAZ), Creative Medical Technology (CELZ), Silexion Therapeutics (SLXN), AIM ImmunoTech (AIM), and Omega Therapeutics (OMGA). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Its Competitors ObsEva Nuvilex GENPREX CEL-SCI Lixte Biotechnology TransCode Therapeutics Creative Medical Technology Silexion Therapeutics AIM ImmunoTech Omega Therapeutics Galera Therapeutics (NASDAQ:GRTX) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability. Which has higher valuation and earnings, GRTX or OBSV? Galera Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.26-0.10ObsEvaN/AN/A-$58.38M-$0.92N/A Is GRTX or OBSV more profitable? Galera Therapeutics' return on equity of 0.00% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% ObsEva N/A -416.36%-92.01% Do insiders & institutionals believe in GRTX or OBSV? 50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor GRTX or OBSV? In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score. Company Overall Sentiment Galera Therapeutics Neutral ObsEva Neutral Which has more volatility & risk, GRTX or OBSV? Galera Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. SummaryGalera Therapeutics and ObsEva tied by winning 4 of the 8 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.92M$773.11M$5.51B$9.47BDividend YieldN/A4.84%4.00%4.04%P/E Ratio-0.071.4228.1819.90Price / SalesN/A24.96426.8892.15Price / CashN/A19.5624.9928.17Price / Book-0.016.938.275.77Net Income-$59.08M-$4.13M$3.24B$257.79M7 Day PerformanceN/A-0.23%1.80%2.77%1 Month PerformanceN/A2.52%9.32%14.17%1 Year PerformanceN/A4.32%35.12%20.71% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.03+1.2%N/A-80.4%$1.92MN/A-0.0730OBSVObsEvaN/AN/AN/AN/A$7.94MN/A-0.1150Gap UpPMCBNuvilex1.6892 of 5 stars$1.10flatN/A-47.4%$7.55MN/A1.494Gap DownGNPXGENPREX0.7533 of 5 stars$0.27+3.9%N/A-85.7%$7.43MN/A0.0020CVMCEL-SCI0.1223 of 5 stars$2.38+3.9%N/A-90.0%$7.23MN/A-4.9743LIXTLixte Biotechnology0.0877 of 5 stars$2.63+17.3%N/A+69.9%$7.22MN/A-1.864RNAZTransCode Therapeutics2.0017 of 5 stars$8.65+7.5%$280.00+3,137.0%-100.0%$7.21MN/A0.009News CoverageAnalyst UpgradeCELZCreative Medical Technology1.0232 of 5 stars$2.72+2.7%N/A-21.8%$7.05M$10K-0.715Gap DownSLXNSilexion TherapeuticsN/A$0.81-1.1%$5.00+521.1%N/A$7.00MN/A0.00N/APositive NewsAIMAIM ImmunoTech1.3627 of 5 stars$9.13+3.2%$275.00+2,912.0%-75.0%$6.98M$146K-19.4320OMGAOmega TherapeuticsN/A$0.13-21.8%$8.50+6,700.0%N/A$6.92M$8.10M-0.09120 Related Companies and Tools Related Companies OBSV Competitors PMCB Competitors GNPX Competitors CVM Competitors LIXT Competitors RNAZ Competitors CELZ Competitors SLXN Competitors AIM Competitors OMGA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRTX Stock Alerts